Send to

Choose Destination
Clin Med Insights Cardiol. 2010 Oct 31;4:99-110. doi: 10.4137/CMC.S5970.

Niacin or ezetimibe for patients with, or at risk of coronary heart disease.

Author information

Professor of Emergency Medicine, Internal Medicine, and Pharmacology, The Ohio State University Columbus, Ohio 43212, USA.


Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy. This paper will examine two of the more popular secondary agents, ezetimibe and niacin, and describe their research data and potential for usefulness in further reducing cardiovascular events.


coronary heart disease; ezetimibe; niacin

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center